Knowthestock.com
ACRX - Acelrx Pharmaceuticals Inc
Compare

Sell

Gross Profit is Negative

19%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -31.03%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -1015.76%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 3.03
Debt Ratio is 1.6
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.22
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Acelrx Pharmaceuticals Inc (ACRX) - www.acelrx.com
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Vincent Angotti
Employees - 54
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.